Teprotumumab for Thyroid-Associated Ophthalmopathy

Overview of attention for article published in New England Journal of Medicine, May 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 71 news outlets
blogs: 7 blogs
policy: 1 policy source
twitter: 110 X users
patent: 25 patents

facebook: 9 Facebook pages
wikipedia: 1 Wikipedia page
googleplus: 2 Google+ users
f1000: 1 research highlight platform
guideline: 4 clinical guideline sources

Readers on

mendeley: 416 Mendeley

So far, Altmetric has seen 124 X posts from 110 X users, with an upper bound of 635,828 followers.

RT @Ashutos15050433: Teprotumumab for Thyroid-Associated Ophthalmopathy | NEJM https://t.co/BCuSN8ybnd

Teprotumumab for Thyroid-Associated Ophthalmopathy | NEJM https://t.co/BCuSN8ybnd

Data on this drug in Graves ophthalmopathy from @NEJM https://t.co/XhDIAGt6v3 https://t.co/DvI0hNcmbH https://t.co/7daEX5b2IU

RT @omlakhani: Teprotumumab is a new drug recently approved for the treatment of Thyroid eye disease (Graves' orbitopathy). It is an antibo…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 120 additional X posts.